Evidence map›Paper›PMID 33586189›Full record

ReviewThe Journal of pathology2021

COVID-19: immunopathology, pathophysiological mechanisms, and treatment options.

Larissa E van Eijk, Mathijs Binkhorst, Arno R Bourgonje, Annette K Offringa, Douwe J Mulder, Eelke M Bos, Nikola Kolundzic, Amaal E Abdulle, Peter Hj van der Voort, Marcel Gm Olde Rikkert and 4 more

Abstract readReview
In one paragraph

Review in The Journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Health-Related Quality of Life and Functional Status of Post-COVID-19 Patients.International journal of environmental research and public health · 2025
    Article
  17. Review
  18. Review
  19. Immune-Related Peripheral Keratopathy in Post-COVID-19 Syndrome.International medical case reports journal · 2025
    Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Larissa E van EijkDepartment of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0003-4280-0164
Mathijs BinkhorstDepartment of Paediatrics, Subdivision of Neonatology, Radboud University Medical Center Amalia Children's Hospital, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-5824-6121
Arno R BourgonjeDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0001-5754-3821
Annette K OffringaMicrobiology and System Biology, Netherlands Organisation for Applied Scientific Research, Zeist, The Netherlands.ORCID https://orcid.org/0000-0003-1332-2466
Douwe J MulderDepartment of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0003-3715-6474
Eelke M BosDepartment of Neurosurgery, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-3647-6740
Nikola KolundzicStem Cell Laboratory, Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.ORCID https://orcid.org/0000-0002-6480-2729
Amaal E AbdulleDepartment of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0003-3766-2238
Peter Hj van der VoortDepartment of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-3486-2843
Marcel Gm Olde RikkertDepartment of Geriatric Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-1397-1677
Johannes G van der HoevenDepartment of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-5362-0244
Wilfred Fa den DunnenDepartment of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-4168-1207
Jan-Luuk HillebrandsDepartment of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0003-3135-3274
Harry van GoorDepartment of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-6670-1577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID-19 cases are characterised by a mild, self-limiting disease course, a considerable subset of patients develop a more severe condition, varying from pneumonia and acute respiratory distress syndrome (ARDS) to multi-organ failure (MOF). Progression of COVID-19 is thought to occur as a result of a complex interplay between multiple pathophysiological mechanisms, all of which may orchestrate SARS-CoV-2 infection and contribute to organ-specific tissue damage. In this respect, dissecting currently available knowledge of COVID-19 immunopathogenesis is crucially important, not only to improve our understanding of its pathophysiology but also to fuel the rationale of both novel and repurposed treatment modalities. Various immune-mediated pathways during SARS-CoV-2 infection are relevant in this context, which relate to innate immunity, adaptive immunity, and autoimmunity. Pathological findings in tissue specimens of patients with COVID-19 provide valuable information with regard to our understanding of pathophysiology as well as the development of evidence-based treatment regimens. This review provides an updated overview of the main pathological changes observed in COVID-19 within the most commonly affected organ systems, with special emphasis on immunopathology. Current management strategies for COVID-19 include supportive care and the use of repurposed or symptomatic drugs, such as dexamethasone, remdesivir, and anticoagulants. Ultimately, prevention is key to combat COVID-19, and this requires appropriate measures to attenuate its spread and, above all, the development and implementation of effective vaccines. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

COVID-19COVID-19 Drug TreatmentAdaptive ImmunityAntiviral AgentsHumansImmunity, InnateSARS-CoV-2United KingdomAntiviral Agentsacute respiratory distress syndrome (ARDS)angiotensin-converting enzyme 2 (ACE2)autoimmunitycoronavirus disease 2019 (COVID-19)diffuse alveolar damage (DAD)immunopathologypathologypathophysiologysevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)treatment

Identifiers

PMID33586189
PMCPMC8013908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.